Karin Jorga, PhD

Publications

A Guide to Rational Dosing of Monoclonal Antibodies

Pharmacokinetics of hedgehog pathway inhibitor GDC-0449 in patients with locally-advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
Clinical Cancer Research, 17; 2512-2520, 2011

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
Clin Pharmacol Ther, 87(6); 706-7013, 2010

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
Journal of Clinical Oncology 27; 4103-4108, 2009

Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon alfa-2a (40KD) plus ribavirin
Liver International, 28(1); 61-71, 2008

An Integrated Glucose-Insulin Model to Describe Oral Glucose Tolerance Test Data in Type 2 Diabetics

Cosson V, Jorga K, Fuseau E
Modelling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set: An Application

Pharmacokinetics of ribavirin in patients with hepatitis C virus
British Journal of Clinical Pharmacology, 62, 710-714, 2006

Snoeck E, Wade J, Duff F, Lamb M, Jorga K.
Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
Jones HM, Parrott N, Jorga K, Lavé T.
A novel strategy for physiologically based predictions of human pharmacokinetics.
Clinical Pharmacokinetics, 45(5), 511-542, 2006

Gueorguieva I, Aarons L, Ogungbenro K, Jorga K, Rodgers T, Rowland M.
Optimal Design of Multivariate Response Pharmacokinetic Models

2002 Coleman MD, Hadley S, Perris AD, Jorga K, Seydel JK
Studies on the toxicity and efficacy of some ester analogues of dapsone in vitro using rat and human tissues
Environment Toxicology and Pharmacology 12, 7-13, 2002

Grub S, Schwarzwald H, Kline M, Jorga K
Pharmacokinetics of saquinavir in children during long-term treatment of HIV infection
The Pediatrics Infectious Disease Journal 21, 712-713, 2002

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection
Clin Pharmacol Ther 71, 122-130, 2002

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Synapse 43, 201-207, 2002

Saquinavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) anti-retroviral therapy
British Journal of Clinical Pharmacology 52, 255-264, 2001

Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.
Pediatr Infect Dis J 20, 666-71, 2001

Grub S, Bryson H, Goggin T, Lüdin E, Jorga K
The interaction of saquinavir (soft gelatin capsules) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and HIV-infected patients
Eur J Clin Pharmacol 57, 115-121, 2001

2000 Jorga KM and van Brummelemen P
Drug Development: Experiences with the COMT-Inhibitor Tolcapone for the Treatment of Parkinson's Disease
MEDCHEM NEWS (Japanese), 10 (3), 2000
Jorga KM, Fotteler B, Modi M, Rabbia M
**Effect of tolcapone on the hemodynamic effects and tolerability of desipramine**

Jorga K, Banken L, Fotteler B, Snell P, Steimer JL
**Population pharmacokinetics of levodopa in parkinsonian patients treated with tolcapone**

Jorga KM, Fotteler B, Gasser R, Banken L
**Lack of interaction between tolcapone and tolbutamide in healthy volunteers**
Journal of Clinical Pharmacology, 40, 544-551, 2000

**Clinical, pharmacokinetic and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated parkinsonian patients**
Clinical Neuropharmacology, 23, 98-105, 2000

Jorga K, Fotteler B, Banken L, Snell P, Steimer JL
**Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies**

1999 Schneider E and Jorga K
**L-DOPA**
In “Neuro-Psychopharmaka”, Bd. 5, 2. Aufl. Riederer P./Laux G./Pöldinger (Hrsg.), Springer-Verlag, Wien, 1999

Jorga KM, Fotteler B, Heizmann P, Gasser R
**Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase**

Jorga KM and Nicholl DJ
**COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/carbidopa (Sinemet®)**

Jorga K.
**L-DOPA Pharmakokinetik unter COMT-Hemmung.**

Gasser UE, Jorga K, Crevoisier C, Hovens SEL, van Giersbergen PLM
**COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide**
Eur. Neurol. 41, 206-211, 1999

**The effect of tolcapone on the pharmacokinetics of benzerazide**
European Journal of Neurology, 6, 211-219, 1999
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy  

The effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites  
Clinical Pharmacology and Therapeutics, 63, 646-54, 1998

Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken JW.  
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation  

Jorga KM.  
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.  
Neurology, 50 (Suppl 5), S29-S36, 1998

Jorga KM.  
COMT Inhibitors: Pharmacokinetic and Pharmacodynamic Comparisons.  

Effect of tolcapone on plasma levodopa levels after coadministration with levodopa/carbidopa to healthy volunteers.  

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.  

Jorga K, Banken L, Fotteler B  
Prospective PK/PD Population Analysis in the Clinical Development of Tolcapone: A COMT Inhibitor for the Treatment of Parkinson's Disease  
In “COST B1, medicine. European cooperation in the field of scientific and technical research. The population approach: measuring and managing variability in response, concentration and dose.” Aarons (ed.), Office for Official Publications of the European Communities (EUR 17611 EN), Luxemburg, 1997

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations.  

Jorga K.  
Pharmakologie der COMT-Hemmer.  
Dingemanse J, Wood N, Jorga KM, Kettler R.
**Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.**

1996
**Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects.**

Da Prada M, Jorga KM.
**Response to Garrido et al.: Side Effects of the Catechol-O-Methyl-Transferase Inhibitor Ro 40-7592 in Rabbits”**

1995
**Pharmacokinetic-Pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.**

**Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.**

Jorga K, Leenders KL, Guenther I, Psylla M.
**COMT inhibition: Pharmacology of tolcapone and 6-[18F]-Fluoro-L-Dopa (FDOPA) PET results.**

1994
Da Prada M, Zuercher G, Kettler R, Dingemanse J, Jorga KM, Dubuis R.
**Inhibiting MAO-B with lazabemide and COMT with tolcapone.**